offline
Pfizer 1Q profit jumps 9% on higher drug sales, lower costs
...
Sales of breast cancer drug Ibrance and blood thinner Eliquis both jumped over 20% to more than $1 billion each in the quarter, and Xeljanz for rheumatoid arthritis saw sales soar 30%, lifting prescription drug sales by 3%.
The New York drugmaker on Tuesday reported net income of $3.88 billion, or 68 cents per share. Earnings, adjusted for non-recurring costs, were 85 cents per share, beating analysts' projections by 8 cents.
...
https://finance.yahoo.com/news/pfizer-1q...26585.html
![[Bild: PFEc1dl1423.png]](https://finviz.com/publish/043019/PFEc1dl1423.png)
...
Sales of breast cancer drug Ibrance and blood thinner Eliquis both jumped over 20% to more than $1 billion each in the quarter, and Xeljanz for rheumatoid arthritis saw sales soar 30%, lifting prescription drug sales by 3%.
The New York drugmaker on Tuesday reported net income of $3.88 billion, or 68 cents per share. Earnings, adjusted for non-recurring costs, were 85 cents per share, beating analysts' projections by 8 cents.
...
https://finance.yahoo.com/news/pfizer-1q...26585.html
__________________
